A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of FG-3019 in Subjects With Type 2 Diabetes Mellitus (DM) and Persistent Proteinuria on Background ACEi and/or ARB Therapy.
Phase of Trial: Phase II
Latest Information Update: 31 Aug 2012
At a glance
- Drugs Pamrevlumab (Primary)
- Indications Diabetic nephropathies; Proteinuria
- Focus Therapeutic Use
- 10 Jan 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 18 Jun 2009 New trial record